

ACTINIC KERATOSIS - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

DICLOFENAC SODIUM 3% GEL, KLISYRI

CRITERIA

Trial of either topical fluorouracil or topical imiquimod

ANTIDEPRESSANTS - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

AUVELITY, EMSAM, FETZIMA, VENLAFAXINE BESYLATE ER

CRITERIA

Trial of two generics of the following formulary products: bupropion, mirtazapine, citalopram (tablet or solution), desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline (tablet or solution), venlafaxine. Approve for continuation of prior therapy.

ATYPICAL ANTIPSYCHOTICS - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

FANAPT, LYBALVI, SECUADO, VRAYLAR

CRITERIA

Trial of two of the following oral generic formulary atypical antipsychotic agents: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone. Approve for continuation of prior therapy.

GLP1 AGONISTS - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

MOUNJARO, OZEMPIC 0.25-0.5 MG/DOSE PEN, OZEMPIC 1 MG/DOSE (4 MG/3 ML), OZEMPIC 2 MG/DOSE (8 MG/3 ML), RYBELSUS, SOLIQUA 100-33, TRULICITY, VICTOZA 2-PAK, VICTOZA 3-PAK

CRITERIA

Trial of one of the following generic formulary metformin or metformin combinations: metformin, metformin ER, glipizide-metformin, glyburide-metformin, pioglitazone-metformin. Ozempic (semaglutide), Trulicity (dulaglutide), Victoza (liraglutide): Step requirements do not apply to members with type 2 diabetes and multiple cardiovascular risk factors or established cardiovascular disease.

GLUCAGON- SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

GLUCAGEN

CRITERIA

Trial of one of the following: Gvoke, Baqsimi, or Glucagon

INHALED CORTICOSTEROID - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

QVAR REDHALER

CRITERIA

Trial of: Arnuity Ellipta and either Flovent Diskus or Flovent HFA

INVEGA HAFYERA THERAPY - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

INVEGA HAFYERA

CRITERIA

Trial of one of the following: Invega Sustenna or Invega Trinza. Step applies to new starts only.
Approve for continuation of prior therapy.

NAMZARIC - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

NAMZARIC

CRITERIA

Trial of generic memantine extended-release

NON-PREFERRED SGLT2S - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

INVOKAMET, INVOKAMET XR, INVOKANA

CRITERIA

Trial of Farxiga or Xigduo XR, AND one of the following: Jardiance, Synjardy, Synjardy XR. Step requirements do not apply to members with type 2 diabetes with either diabetic nephropathy or established cardiovascular disease.

PD AGENTS - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

NEUPRO

CRITERIA

Trial of one of the following generic formulary dopamine agonist agent: pramipexole, ropinirole

RELISTOR - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

RELISTOR

CRITERIA

Trial of lubiprostone or lactulose

RYTARY - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

RYTARY

CRITERIA

Trial of one generic carbidopa/levodopa containing formulation

STATINS - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

LIVALO

CRITERIA

Trial of any one of the following generic formulary HMG-CoA reductase inhibitors (statin):
atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin

ZONISADE SUSPENSION - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

ZONISADE

CRITERIA

Trial of generic zonisamide capsule. Step applies to new starts only. Approve for continuation of prior therapy.